Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-BD: Sequential Multiple Assignment Randomized Trial for Bipolar Depression
NCT06433635Phase 4Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2024
- Primary completion
- Feb 2030
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 4 trial of cariprazine, aripiprazole, escitalopram, quetiapine, lurasidone in bipolar disorder (BD), sponsored by Massachusetts General Hospital. Started Oct 2024; status: active, not recruiting.
02
Drugs
cariprazinearipiprazoleescitalopramquetiapinelurasidone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06433635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433635.